2. Signaling Pathways
  3. GPCR/G Protein
  4. GCGR

GCGR

Glucagon Receptor

GCGR

Related Products

PDF 0.98 MB

GCGR (glucagon receptor) is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-142162
    LSN3318839
    		Modulator 99.22%
    LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar.
    LSN3318839
  • HY-10930
    UNC0321
    		Inhibitor 99.91%
    UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a Ki of 63 pM and with assay-dependent IC50 values of 6-9 nM. UNC0321 also inhibits GLP with assay-dependent IC50 values of 15-23 nM. UNC0321 has anti-apoptotic activity and has potential application in diabetic vascular complications.
    UNC0321
  • HY-P0165
    Taspoglutide
    		Agonist 99.43%
    Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.
    Taspoglutide
  • HY-P99383
    Volagidemab
    		Antagonist ≥99.0%
    Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D).
    Volagidemab
  • HY-P0150
    Glucagon (19-29), human
    		Inhibitor 99.11%
    Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.
    Glucagon (19-29), human
  • HY-P2625
    GLP-2(3-33)
    		Agonist 99.82%
    GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC50=5.8 nM).
    GLP-2(3-33)
  • HY-P0014S1
    Liraglutide-13C5,15N tetraTFA
    		Agonist
    Liraglutide-13C6,15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
    Liraglutide-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N tetraTFA
  • HY-P2221B
    Glepaglutide acetate
    		Agonist 99.48%
    Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease.
    Glepaglutide acetate
  • HY-P1144
    Oxyntomodulin (bovine, porcine)
    		Agonist 99.77%
    Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist.
    Oxyntomodulin (bovine, porcine)
  • HY-P1145A
    Glucagon-like peptide 1 (1-37), human TFA
    		Agonist 99.55%
    Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.
    Glucagon-like peptide 1 (1-37), human TFA
  • HY-P3469A
    Dasiglucagon acetate
    		98.66%
    Dasiglucagon acetate is a human glucagon analog, and can increase plasma glucose. Dasiglucagon can be used in hypoglycemia research.
    Dasiglucagon acetate
  • HY-19947
    PF-06291874
    		Antagonist 99.31%
    PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM).
    PF-06291874
  • HY-P3101
    GLP-1(28-36)amide
    		99.18%
    GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects.
    GLP-1(28-36)amide
  • HY-P1348
    GLP-1 moiety from Dulaglutide
    		99.60%
    GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide. GLP-1 moiety from Dulaglutide is a glucagon-like peptide 1 receptor (GLP-1) agonist. Dulaglitude can be used in researches of diabetes and myocardial injury.
    GLP-1 moiety from Dulaglutide
  • HY-116819
    VU0453379
    		Modulator 98.0%
    VU0453379 is a blood-brain barrier permeable GLP-1R positive allosteric modulator (PAM) with an EC50 value of 1.3 μM. VU0453379 potentiates the actions of endogenous GLP-1 and synthetic peptide agonists, and promotes GLP-1 receptor internalization. VU0453379 stimulates insulin secretion from primary mouse islets. VU0453379 enhances the function of endogenous GLP-1R and reverses catalepsy in animal models. VU0453379 is useful for research on Parkinson's disease and type 2 diabetes.
    VU0453379
  • HY-103547
    L-168049
    		Antagonist 99.94%
    L-168049 is a potent, selective, orally active and non-competitive glucagon receptor antagonist with IC50s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively.
    L-168049
  • HY-P4146A
    Survodutide TFA
    		Agonist 99.39%
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.
    Survodutide TFA
  • HY-145632
    Pemvidutide
    		Agonist 99.40%
    Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research.
    Pemvidutide
  • HY-P1143A
    [Des-His1,Glu9]-Glucagon amide TFA
    		Antagonist 98.36%
    [Des-His1,Glu9]-Glucagon amide TFA is a potent and peptide antagonist of the glucagon receptor, with a pA2 of 7.2. [Des-His1,Glu9]-Glucagon amide TFA is potentially useful in the study of the pathogenesis of diabetes.
    [Des-His1,Glu9]-Glucagon amide TFA
  • HY-N0630
    Shanzhiside methyl ester
    		Agonist 99.97%
    Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance.
    Shanzhiside methyl ester
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity